Intramuscular injection of precursor cells offers the advantage of injecting cells close to the ulcer, which stimulates paracrine activity and the release of angiogenic cytokines such as VEGF (vascular endothelial growth factor), bFGF (basic fibroblast growth factor) and others. The gene discussed is FGF2; the disease is ulcer disease.